U.S. group says Novartis MS drug price out of line with benefit
A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients.
from Reuters: Health News https://reut.rs/2IuFF3h
http://bit.ly/2zwRqiM